| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
(1) Investigation of etiology and disease modifier factors in hypertrophic cardiomyopathy (HCM): We performed genetic analysis in patients with HCM and reported double sarcomere mutations in HCM patients as first Japanese cases. We identified one of disease modifier factors, that is gender differences, and found that female patients with MYBPC3 were more symptomatic at diagnosis and had more frequent heart failure events once they had developed hypertrophy.
(2) Investigation of prognostic biomarkers in HCM: We focused on biomarkers including brain natriuretic peptide, cardiac troponins, tenascin-C, etc., and found that these biomarkers were useful to predict outcome in patients with HCM. Furthermore, we reported that tissue Doppler indeces on echocardiography were useful to predict clinical outcome even in asymptomatic or mildly symptomatic patiients with HCM.
|
